Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride

A pilot study

Nelson L Rhodus, William Liljemark, Cynthia Bloomquist, Janna Bereuter

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: The purpose of this study was to compare the quantities of oral Candida albicans in patients with primary and secondary Sjögren's syndrome before and after the use of orally administered pilocarpine hydrochloride for 1 year. Method and materials: Twelve female subjects with primary (n = 4) and secondary (n = 8) Sjögren's syndrome (mean age ± SEM = 56.7 ± 5.7 years) were enrolled in the study, after meeting rigid enrollment criteria. Oropharyngeal collection of samples and culturing was performed on each subject. Cultures specific for Candida albicans were plated into a culture media tube using the Oricult kit and also by serial dilutions and plating by a streptomycin-vancomycin technique. Cultures were incubated for 48 hours at 37°C. The subjects used 5 mg of pilocarpine hydrochloride, administered orally three times daily, for 1 year, after which both of the Candida cultures were repeated. None of the subjects used antifungal medications, none smoked, and all were dentate. Results: There was a significant difference in the prevalence of Candida after the use of pilocarpine hydrochloride for both groups. At the start of the study, 75% of all subjects were positive for Candida. Following the use of pilocarpine, 25% had positive cultures. There was also a decrease in the prevalence of clinical manifestations of infection from 75% of subjects to 25%. There was a significant decrease in the numbers of Candida cultured following the use of pilocarpine. Conclusion: Long-term administration of pilocarpine hydrochloride resulted in a significant reduction in Candida albicans colonization in patients with primary or secondary Sjögren's syndrome.

Original languageEnglish (US)
Pages (from-to)705-710
Number of pages6
JournalQuintessence International
Volume29
Issue number11
StatePublished - Nov 1 1998

Fingerprint

Pilocarpine
Candida albicans
Candida
Streptomycin
Vancomycin
Culture Media
Infection

Keywords

  • Candida albicans
  • Pilocarpine hydrochloride
  • Saliva
  • Sjögren's syndrome
  • Xerostomia
  • Yeast

Cite this

Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride : A pilot study. / Rhodus, Nelson L; Liljemark, William; Bloomquist, Cynthia; Bereuter, Janna.

In: Quintessence International, Vol. 29, No. 11, 01.11.1998, p. 705-710.

Research output: Contribution to journalArticle

@article{06ffa4fe17754a88b3edacf1a017f5fe,
title = "Candida albicans levels in patients with Sj{\"o}gren's syndrome before and after long-term use of pilocarpine hydrochloride: A pilot study",
abstract = "Objective: The purpose of this study was to compare the quantities of oral Candida albicans in patients with primary and secondary Sj{\"o}gren's syndrome before and after the use of orally administered pilocarpine hydrochloride for 1 year. Method and materials: Twelve female subjects with primary (n = 4) and secondary (n = 8) Sj{\"o}gren's syndrome (mean age ± SEM = 56.7 ± 5.7 years) were enrolled in the study, after meeting rigid enrollment criteria. Oropharyngeal collection of samples and culturing was performed on each subject. Cultures specific for Candida albicans were plated into a culture media tube using the Oricult kit and also by serial dilutions and plating by a streptomycin-vancomycin technique. Cultures were incubated for 48 hours at 37°C. The subjects used 5 mg of pilocarpine hydrochloride, administered orally three times daily, for 1 year, after which both of the Candida cultures were repeated. None of the subjects used antifungal medications, none smoked, and all were dentate. Results: There was a significant difference in the prevalence of Candida after the use of pilocarpine hydrochloride for both groups. At the start of the study, 75{\%} of all subjects were positive for Candida. Following the use of pilocarpine, 25{\%} had positive cultures. There was also a decrease in the prevalence of clinical manifestations of infection from 75{\%} of subjects to 25{\%}. There was a significant decrease in the numbers of Candida cultured following the use of pilocarpine. Conclusion: Long-term administration of pilocarpine hydrochloride resulted in a significant reduction in Candida albicans colonization in patients with primary or secondary Sj{\"o}gren's syndrome.",
keywords = "Candida albicans, Pilocarpine hydrochloride, Saliva, Sj{\"o}gren's syndrome, Xerostomia, Yeast",
author = "Rhodus, {Nelson L} and William Liljemark and Cynthia Bloomquist and Janna Bereuter",
year = "1998",
month = "11",
day = "1",
language = "English (US)",
volume = "29",
pages = "705--710",
journal = "Quintessence international (Berlin, Germany : 1985)",
issn = "0033-6572",
publisher = "Quintessence Publishing Company",
number = "11",

}

TY - JOUR

T1 - Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride

T2 - A pilot study

AU - Rhodus, Nelson L

AU - Liljemark, William

AU - Bloomquist, Cynthia

AU - Bereuter, Janna

PY - 1998/11/1

Y1 - 1998/11/1

N2 - Objective: The purpose of this study was to compare the quantities of oral Candida albicans in patients with primary and secondary Sjögren's syndrome before and after the use of orally administered pilocarpine hydrochloride for 1 year. Method and materials: Twelve female subjects with primary (n = 4) and secondary (n = 8) Sjögren's syndrome (mean age ± SEM = 56.7 ± 5.7 years) were enrolled in the study, after meeting rigid enrollment criteria. Oropharyngeal collection of samples and culturing was performed on each subject. Cultures specific for Candida albicans were plated into a culture media tube using the Oricult kit and also by serial dilutions and plating by a streptomycin-vancomycin technique. Cultures were incubated for 48 hours at 37°C. The subjects used 5 mg of pilocarpine hydrochloride, administered orally three times daily, for 1 year, after which both of the Candida cultures were repeated. None of the subjects used antifungal medications, none smoked, and all were dentate. Results: There was a significant difference in the prevalence of Candida after the use of pilocarpine hydrochloride for both groups. At the start of the study, 75% of all subjects were positive for Candida. Following the use of pilocarpine, 25% had positive cultures. There was also a decrease in the prevalence of clinical manifestations of infection from 75% of subjects to 25%. There was a significant decrease in the numbers of Candida cultured following the use of pilocarpine. Conclusion: Long-term administration of pilocarpine hydrochloride resulted in a significant reduction in Candida albicans colonization in patients with primary or secondary Sjögren's syndrome.

AB - Objective: The purpose of this study was to compare the quantities of oral Candida albicans in patients with primary and secondary Sjögren's syndrome before and after the use of orally administered pilocarpine hydrochloride for 1 year. Method and materials: Twelve female subjects with primary (n = 4) and secondary (n = 8) Sjögren's syndrome (mean age ± SEM = 56.7 ± 5.7 years) were enrolled in the study, after meeting rigid enrollment criteria. Oropharyngeal collection of samples and culturing was performed on each subject. Cultures specific for Candida albicans were plated into a culture media tube using the Oricult kit and also by serial dilutions and plating by a streptomycin-vancomycin technique. Cultures were incubated for 48 hours at 37°C. The subjects used 5 mg of pilocarpine hydrochloride, administered orally three times daily, for 1 year, after which both of the Candida cultures were repeated. None of the subjects used antifungal medications, none smoked, and all were dentate. Results: There was a significant difference in the prevalence of Candida after the use of pilocarpine hydrochloride for both groups. At the start of the study, 75% of all subjects were positive for Candida. Following the use of pilocarpine, 25% had positive cultures. There was also a decrease in the prevalence of clinical manifestations of infection from 75% of subjects to 25%. There was a significant decrease in the numbers of Candida cultured following the use of pilocarpine. Conclusion: Long-term administration of pilocarpine hydrochloride resulted in a significant reduction in Candida albicans colonization in patients with primary or secondary Sjögren's syndrome.

KW - Candida albicans

KW - Pilocarpine hydrochloride

KW - Saliva

KW - Sjögren's syndrome

KW - Xerostomia

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=0032195979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032195979&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 705

EP - 710

JO - Quintessence international (Berlin, Germany : 1985)

JF - Quintessence international (Berlin, Germany : 1985)

SN - 0033-6572

IS - 11

ER -